Name | 3-[(3,4-dichlorophenyl)methylamino]propyl-(diethoxymethyl)phosphinic acid |
---|---|
Synonyms |
Tocris-1246
MFCD00041095 [3-[[(3,4-Dichlorophenyl)methyl]amino]propyl](diethoxymethyl)-phosphinic acid CGP52432 |
Description | CGP52432 is a GABAB receptor antagonist, with an IC50 of 85 nM. |
---|---|
Related Catalog | |
Target |
IC50: 85 nM (GABAB receptor)[1] |
In Vitro | CGP52432 is a GABAB receptor antagonist, with an IC50 of 85 nM, 35- and 100-fold lower than at the receptors regulating somatostatin and glutamate overflow, respectively[1]. |
In Vivo | CGP52432 (10, 30 mg/kg) shows no effect on the total arm entries and total head dips of mice on the elevated-plus maze[2]. CGP52432 (100 nmol/kg, i.v., or 1 nmol/kg, i.c.v.) abolishes the suppressive effects of GABA ( 50 μmol/kg, i.v.) on enhanced renal sympathetic nerve activity (RSNA) during ischaemia, causeing elimination of the renoprotective effects of GABA in rats[3]. |
Animal Admin | Mice[2] Two separate cohorts of male pups are used for the study. One cohort is treated with either R(+)baclofen HCl (2 mg/kg) or with vehicle (PBS). The second cohort is treated with the GABAB receptor antagonist CGP52342 (10, 30 mg/kg) or vehicle (PBS). Drugs are freshly prepared for injection each day, by dissolution in PBS with vortexing and brief sonication. Doses of R(+)baclofen and CGP52432 are chosen to be well tolerated in adult mice. All drug treatments are given via subcutaneous injection, once daily from P14-28 in a volume of 0.05 mL[2]. |
References |
Density | 1.258g/cm3 |
---|---|
Boiling Point | 544.4ºC at 760mmHg |
Molecular Formula | C15H24Cl2NO4P |
Molecular Weight | 384.23500 |
Flash Point | 283.1ºC |
Exact Mass | 383.08200 |
PSA | 77.60000 |
LogP | 4.49100 |
Vapour Pressure | 1.1E-12mmHg at 25°C |
Index of Refraction | 1.524 |
Storage condition | 2-8℃ |
RIDADR | NONH for all modes of transport |
---|